In light of these findings, a phase I/II clinical trial is underway to demonstrate the safety and efficacy of CRISPR/Cas9 gene therapy via subretinal delivery in patients with Leber Congenital Amaurosis Type 10 (LCA10), which is caused by the IVS26 mutation in the CEP290 gene (NCT03872479). Here, CEP290 is linked to Leber congenital amaurosis 10.